N-Acetyl Semax Amidate

1. Overview

N-Acetyl Semax Amidate is a dual-modified derivative of Semax, the synthetic heptapeptide nootropic developed at the Institute of Molecular Genetics of the Russian Academy of Sciences [3][11]. It carries two chemical modifications to the parent Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro): an acetyl group on the N-terminus and an amide group replacing the C-terminal carboxyl group, yielding the structure Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2.

This dual modification strategy addresses the two primary enzymatic degradation pathways for small peptides in biological systems [9][10]:

1. N-terminal acetylation blocks aminopeptidases, which cleave amino acids sequentially from the unprotected N-terminus
2. C-terminal amidation blocks carboxypeptidases, which cleave amino acids from the C-terminal carboxyl group

By protecting both termini simultaneously, N-Acetyl Semax Amidate achieves the maximum possible enzymatic resistance among Semax variants, representing a hierarchy of stability: Semax (unmodified, shortest half-life) to N-Acetyl Semax (N-terminal protection only) to N-Acetyl Semax Amidate (dual protection, longest half-life).

Semax itself was designed as a stabilized analog of the ACTH(4-10) fragment, with the Pro-Gly-Pro extension at the C-terminus already providing some endopeptidase resistance [11]. The additional terminal modifications build upon this foundation to create a peptide with substantially greater metabolic stability, potentially translating to improved CNS bioavailability after intranasal or systemic administration [12].

Like its parent compound, N-Acetyl Semax Amidate is expected to upregulate BDNF and NGF expression, provide neuroprotection against ischemic injury, enhance attention and memory, and modulate dopaminergic, serotonergic, and cholinergic neurotransmission [1][4][8]. No independent clinical trial data has been published for this dual-modified form.

Parent Peptide

Semax (Met-Glu-His-Phe-Pro-Gly-Pro)

Modifications

N-terminal acetylation + C-terminal amidation

Structure

Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2

Molecular Weight

~854.98 Da

Half-life

Extended (longest among Semax variants); exact value not published

Routes Studied

Intranasal, subcutaneous

FDA Status

Not approved; Semax approved in Russia only

Key Advantage

Maximum enzymatic resistance via dual N- and C-terminal protection

2. Mechanism of Action

The mechanism of action of N-Acetyl Semax Amidate is expected to be identical to that of unmodified Semax, as neither the N-terminal acetylation nor the C-terminal amidation alters the internal peptide sequence responsible for biological activity.

Neurotrophic Factor Upregulation

Semax potently upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus and basal forebrain [1][8]. Eremin et al. (2005) showed increased BDNF mRNA expression within 30 minutes of intranasal Semax [1]. Dolotov et al. (2006) demonstrated parallel increases in NGF expression and enhanced cholinergic neuron survival [4]. BDNF is a critical mediator of synaptic plasticity, long-term potentiation, and neuronal survival, making its upregulation a plausible mechanism for both the nootropic and neuroprotective effects of Semax and its derivatives.

Neuroprotection

In cerebral ischemia models, Semax prevents neuronal death through multiple mechanisms: anti-apoptotic gene activation, immunomodulatory gene regulation, and vascular gene expression changes [5][6]. Transcriptomic analysis revealed that Semax modulates expression of genes involved in immune response, apoptosis, and vascular regulation within hours of ischemic onset [6].

Cognitive Enhancement

Semax improves attention and short-term memory in healthy volunteers [3], effects attributed to enhanced dopaminergic and serotonergic signaling in prefrontal and hippocampal circuits, combined with neurotrophic factor-mediated synaptic strengthening [1][4].

3. The Dual Modification Strategy

N-Terminal Acetylation

The acetyl group (CH3CO-) replaces the free alpha-amino group's hydrogen, converting the primary amine to an amide bond. This modification eliminates recognition by aminopeptidases, which require a free N-terminal amino group for substrate binding [9][10]. The modification also eliminates the positive charge on the N-terminus, marginally increasing lipophilicity.

C-Terminal Amidation

The C-terminal carboxyl group (-COOH) is converted to a carboxamide (-CONH2). This modification eliminates recognition by carboxypeptidases, which require a free C-terminal carboxyl group for substrate binding [9]. C-terminal amidation is one of the most common post-translational modifications found in naturally occurring bioactive peptides -- approximately half of all known neuropeptides are naturally amidated, as the modification often enhances receptor affinity and biological potency in addition to improving stability [9].

Hierarchy of Semax Variants

The three Semax variants represent a stability hierarchy:

Semax (unmodified): Met-Glu-His-Phe-Pro-Gly-Pro

• Vulnerable to both aminopeptidases and carboxypeptidases
• Half-life: several minutes
• The Pro-Gly-Pro extension provides some endopeptidase resistance

N-Acetyl Semax: Ac-Met-Glu-His-Phe-Pro-Gly-Pro

• Protected from aminopeptidases; still vulnerable to carboxypeptidases
• Half-life: extended (exact value not published)
• Improved stability over unmodified Semax

N-Acetyl Semax Amidate: Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2

• Protected from both aminopeptidases and carboxypeptidases
• Half-life: longest among variants (exact value not published)
• Maximum enzymatic resistance
• The amidation may additionally enhance receptor interactions

Practical Implications

The dual modification is expected to produce the longest duration of action among Semax variants, potentially allowing the lowest effective dose and least frequent administration. For intranasal delivery, longer stability during mucosal transit may increase the fraction of peptide that successfully crosses the nasal epithelium and reaches the CNS [12]. For systemic (subcutaneous) administration, the extended half-life would increase the area under the curve (AUC) for any given dose.

4. Researched Applications

All researched applications are based on the Semax literature, as N-Acetyl Semax Amidate has not been independently studied:

Cognitive Enhancement

Evidence level: Moderate (clinical trials with Semax)

Kaplan et al. (1996) demonstrated improved attention and short-term memory in a randomized trial of healthy volunteers [3]. The nootropic effects are attributed to BDNF-mediated synaptic plasticity enhancement and cholinergic system support [4]. N-Acetyl Semax Amidate would be expected to produce the most sustained cognitive enhancement among Semax variants due to its maximum stability.

Stroke and Cerebral Ischemia

Evidence level: Moderate (clinical trials with Semax)

Gusev et al. (2005) showed that intranasal Semax (12 mg/day) accelerated neurological recovery in 100 acute ischemic stroke patients compared to placebo [2]. The neuroprotective mechanism involves rapid neurotrophic factor upregulation, anti-apoptotic signaling, and immune gene modulation [5][6].

Neuroregeneration

Evidence level: Preliminary (in vitro with Semax)

Grivennikov et al. (2008) demonstrated that Semax promoted neuronal differentiation and neurite outgrowth in embryonic brain cultures [13], suggesting potential neuroregenerative applications.

Spinal Cord Injury and Alzheimer's Disease (Emerging 2025 Research)

Evidence level: Preliminary (preclinical)

In 2025, new preclinical studies expanded Semax's profile. A study in the British Journal of Pharmacology demonstrated that Semax improved functional recovery after spinal cord injury in mice via mu-opioid receptor targeting and USP18-mediated deubiquitination. Separately, Semax and a derivative showed cognitive improvements in transgenic Alzheimer's mouse models. These emerging results for the parent compound are relevant to N-Acetyl Semax Amidate, which would be expected to produce the same qualitative effects with potentially enhanced CNS bioavailability due to its dual terminal protection.

5. Clinical Evidence Summary

6. Dosing in Research

No established dosing protocols exist for N-Acetyl Semax Amidate. The following reflects Semax dosing from published studies. The dual-modified form may require lower doses due to enhanced stability.

7. Safety and Side Effects

Semax has demonstrated a favorable safety profile across Russian clinical trials and regulatory approval, with no significant adverse effects reported at therapeutic doses [2][3]. The peptide does not stimulate cortisol release or affect the adrenal axis, as its ACTH(4-10) derivation deliberately excluded the steroidogenic ACTH(1-3) domain [11].

N-Acetyl Semax Amidate is expected to share this safety profile. Both modifications -- acetylation and amidation -- are standard pharmaceutical chemistry techniques applied to numerous approved peptide drugs. C-terminal amidation in particular is found in many naturally occurring neuropeptides (oxytocin, vasopressin, calcitonin, GnRH, and others) and is considered a well-tolerated modification.

The extended half-life of the dual-modified form means that any pharmacological effects, including any potential adverse effects, would persist longer per dose compared to unmodified Semax. No specific safety data has been published for N-Acetyl Semax Amidate, and it remains unregulated outside of research contexts.

8. Pharmacokinetics

No formal pharmacokinetic studies have been published for N-Acetyl Semax Amidate. The available pharmacokinetic understanding is inferred from the parent compound Semax and from general principles of peptide modification chemistry.

Unmodified Semax has a plasma half-life of only several minutes when administered intranasally, with rapid degradation by aminopeptidases and carboxypeptidases [9][10]. N-Acetyl Semax (single modification) extends this half-life by blocking N-terminal degradation, while the dual-modified N-Acetyl Semax Amidate is expected to confer the longest half-life by simultaneously blocking both degradation pathways. However, the exact plasma half-life, bioavailability, volume of distribution, and clearance parameters for N-Acetyl Semax Amidate remain unpublished.

For intranasal administration, Semax and its derivatives are believed to reach the CNS via direct nose-to-brain transport along the olfactory and trigeminal nerve pathways, partially bypassing the blood-brain barrier [12]. The dual modification may improve the fraction of intact peptide surviving mucosal transit. For subcutaneous administration, absorption into systemic circulation followed by blood-brain barrier transport is the presumed route, with the extended half-life predicted to increase the area under the curve (AUC).

The absence of published pharmacokinetic data for the dual-modified form is a significant gap. Without defined bioavailability, half-life, and CNS penetration parameters, rational dose selection remains speculative. The assumption that lower doses are needed compared to Semax is pharmacologically reasonable but unverified.

9. Dose-Response

No dose-response studies have been conducted for N-Acetyl Semax Amidate. Dosing is entirely extrapolated from the unmodified Semax literature.

For Semax, a dose-dependent relationship has been observed in clinical and preclinical settings: 200-600 mcg intranasally (0.1% solution) for cognitive enhancement [3], and up to 12 mg/day for acute stroke [2]. The fMRI study by Ershov et al. demonstrated measurable CNS effects within 20 minutes of intranasal Semax [7], establishing a lower bound for onset of action. BDNF mRNA upregulation occurs within 30 minutes at standard intranasal doses [1].

Given the expected 2-4 fold increase in effective exposure from dual terminal protection, N-Acetyl Semax Amidate would theoretically require proportionally lower doses to achieve equivalent pharmacodynamic effects. However, the dose-response curve may not be linear -- the relationship between peptide stability, receptor engagement kinetics, and neurotrophic factor upregulation has not been characterized for any Semax variant. Users in the research community typically reference doses of 100-300 mcg intranasally, lower than standard Semax doses, but these are convention-based rather than evidence-based.

10. Comparative Effectiveness

N-Acetyl Semax Amidate exists within a hierarchy of three Semax variants, each with a different stability profile but the same core pharmacology. No head-to-head comparison studies have been published for any pair of these variants.

Vs. Semax (unmodified): Semax has the strongest evidence base, including Russian regulatory approval, multiple RCTs in stroke, and demonstrated cognitive enhancement in healthy volunteers [2][3]. Its short half-life necessitates frequent dosing (2-3 times daily). N-Acetyl Semax Amidate would be expected to produce longer-lasting effects per dose but lacks any independent clinical validation.

Vs. N-Acetyl Semax: The single-modified form provides intermediate stability. The added benefit of C-terminal amidation (in the dual-modified form) over N-terminal acetylation alone is theoretically sound from an enzymology perspective but has not been quantified in comparative bioavailability or efficacy studies.

Vs. Selank: Selank is another Russian ACTH-derived peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with anxiolytic rather than primarily nootropic effects. While both upregulate neurotrophic factors, Selank acts more through the tryptophan hydroxylase and enkephalin systems, making the two peptides complementary rather than directly comparable.

Vs. Noopept: Noopept is a small-molecule nootropic (not a peptide in the traditional sense) with oral bioavailability and established Russian clinical data. It acts through a different mechanism (cycloprolylglycine metabolite, AMPA modulation) and represents an alternative rather than a competitor to the Semax family.

11. Enhanced Safety

The safety profile of N-Acetyl Semax Amidate is inferred from the parent compound Semax, which has demonstrated favorable tolerability across Russian clinical trials spanning decades [2][3][11]. Semax was specifically engineered to exclude the ACTH(1-3) N-terminal sequence responsible for adrenal cortisol stimulation, eliminating hormonal side effects that would otherwise accompany an ACTH-derived peptide [11].

Both chemical modifications applied to create N-Acetyl Semax Amidate are well-established in pharmaceutical chemistry. N-terminal acetylation is used in numerous approved drugs and naturally occurring peptides (e.g., alpha-MSH). C-terminal amidation is a common post-translational modification found in approximately half of all known neuropeptides, including oxytocin, vasopressin, calcitonin, and GnRH [9]. Neither modification introduces novel pharmacological risk.

The primary safety consideration unique to the dual-modified form is the extended duration of pharmacological effects. Any adverse effect -- whether from excessive BDNF stimulation, neurotransmitter modulation, or off-target activity -- would persist longer per dose than with unmodified Semax. This extended exposure window could be clinically relevant in individuals with seizure disorders (given BDNF's role in excitatory neurotransmission) or those taking serotonergic medications.

No reports of serious adverse events have emerged from the research peptide community's use of N-Acetyl Semax Amidate, though this observation is subject to severe reporting bias. The peptide remains unregulated, with no pharmacovigilance monitoring, no standardized purity requirements for commercial sources, and no drug interaction data.

12. Related Peptides

See also: Semax, N-Acetyl Semax, Selank, Noopept

13. References

1. [1] Eremin KO, Kudrin VS, Saranseva SE, et al. (2005). Semax, an ACTH(4-10) analog with nootropic properties, activates dopaminergic and serotonergic brain systems in rodents. Neurochem Res. PubMed
2. [2] Gusev EI, Skvortsova VI, Izhboldina GI, et al. (2005). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. PubMed
3. [3] Kaplan AY, Kochetova AG, Nezavibatko VN, et al. (1996). Synthetic ACTH analogue semax displays nootropic-like activity in humans. Neurosci Res Commun. PubMed
4. [4] Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive enhancing properties, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. PubMed
5. [5] Levitskaya NG, Vilkov GA, Makarov VL, et al. (2004). Neuroprotective effects of semax in incomplete global cerebral ischemia. Bull Exp Biol Med. PubMed
6. [6] Medvedeva EV, Dmitrieva VG, Limborska SA, et al. (2014). Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. PubMed
7. [7] Ershov FI, Uchakin PN, Ershova OA, et al. (2020). Functional connectomic study of the effects of selank and semax on resting brain activity. Hum Brain Mapp. PubMed
8. [8] Dolotov OV, Karpenko EA, Seredenina TS, et al. (2003). Semax increases expression of BDNF gene and its receptor TrkB in rat hippocampus. Dokl Biochem Biophys. PubMed
9. [9] Werle M, Bernkop-Schnurch A (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. DOI PubMed
10. [10] Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research. DOI PubMed
11. [11] Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. (1995). Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and hydrophobic radicals. Neurosci Res Commun.
12. [12] Banks WA (2015). Peptides and the blood-brain barrier. Peptides. DOI PubMed
13. [13] Grivennikov IA, Dolotov OV, Goldina YI (2008). Peptide drugs of neurotrophin superfamily. Neurochem J. PubMed